Zymeworks (ZYME) Projected to Post Quarterly Earnings on Thursday

Zymeworks (NASDAQ:ZYME) is expected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $24.3760 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.55) EPS for the quarter. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. The business had revenue of $2.52 million during the quarter. On average, analysts expect Zymeworks to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zymeworks Stock Up 1.3%

Shares of NASDAQ ZYME traded up $0.34 during trading on Wednesday, hitting $27.02. The company had a trading volume of 30,269 shares, compared to its average volume of 701,490. The stock has a fifty day simple moving average of $25.47 and a two-hundred day simple moving average of $23.94. Zymeworks has a fifty-two week low of $10.86 and a fifty-two week high of $29.75. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -24.98 and a beta of 1.20.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZYME. Truist Financial upgraded shares of Zymeworks to a “strong-buy” rating in a research report on Monday, April 27th. Leerink Partners lifted their price target on Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Monday, April 20th. HC Wainwright lifted their price target on Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, Stifel Nicolaus lifted their price target on Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zymeworks has an average rating of “Moderate Buy” and an average price target of $37.89.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP boosted its position in Zymeworks by 22.1% during the fourth quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock worth $151,398,000 after acquiring an additional 1,039,449 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Zymeworks by 53.5% in the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after acquiring an additional 615,000 shares during the last quarter. Siren L.L.C. purchased a new position in shares of Zymeworks during the 4th quarter worth $44,238,000. Deutsche Bank AG raised its holdings in shares of Zymeworks by 3.3% during the 4th quarter. Deutsche Bank AG now owns 1,595,833 shares of the company’s stock worth $42,018,000 after acquiring an additional 50,935 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Zymeworks by 851.6% during the 3rd quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock valued at $18,870,000 after acquiring an additional 988,711 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.